Human Genome Sciences Announces $40 Million Milestone Payment Related to Albuferon Development

Human Genome Sciences, Inc. announced that it will receive a $40 million payment from Novartis in September 2007 for the previously reported successful completion of a Phase 2b trial of Albuferon (albinterferon alfa-2b) in treatment-naive patients with chronic hepatitis C.
PR Newswire